AXIM Biotechnologies, Inc. (AXIM) Fair Value 2026

AXIM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, AXIM Biotechnologies, Inc. (AXIM) trades at $0.00. QOC: 4.6/10. Value Trap Risk: 35/100 (LOW). 1/13 models active.

Key Facts

Ticker
AXIM
Price
$0.00
Quality Score
4.6/10
Value Trap Risk
35/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +55.5% upside with 23% confidence
Risk: Below-average Quality Score of 4.6/10 signals weak fundamentals

What Fair Value Does Each Model Give AXIM?

1 Intrinsic Value Models vs. Current Price ($0.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.01 +55.5%

All Models Active

All 1 models are displayed above.

What Is AXIM Biotechnologies, Inc. (AXIM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for AXIM Biotechnologies, Inc.. Trading at $0.00 against an estimated intrinsic value of $0.01, 1 of 1 active models flag meaningful upside of +55.5% at the median.

What Do the Models Say About AXIM?

1 of 13 models are currently active for AXIM. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does AXIM Rank in Biotechnology?

Among 620 Biotechnology stocks, AXIM ranks #417 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, AXIM Biotechnologies, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating AXIM should weigh these sector-specific dynamics alongside our model-derived fair values.

Is AXIM a Value Trap?

CirclFi's Value Trap algorithm assigns AXIM a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for AXIM Biotechnologies, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, AXIM Biotechnologies, Inc.'s fundamental quality profile registers 4.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AXIM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AXIM's 1 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AXIM Biotechnologies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NMRANeumora Therapeutics, Inc.QOC 4.6SNTISenti Biosciences Holdings, Inc.QOC 4.6BMEABiomea Fusion, Inc.QOC 4.6NTHINeOnc Technologies Holdings, Inc.QOC 4.6BDRXBiodexa Pharmaceuticals PlcQOC 4.6AVTXAvalo Therapeutics, Inc.QOC 4.6XCURExicure, Inc.QOC 3.5TCRXTScan Therapeutics, Inc.QOC 6.4AVIRAtea Pharmaceuticals, Inc.QOC 5.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NMRA · SNTI · BMEA · NTHI · BDRX · AVTX · XCUR · TCRX · AVIR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AXIM?

5 companies across all industries closest to AXIM’s Quality of Company score of 4.6/10.

DXRDaxor CorporationQOC 4.6EURKEureka Acquisition CorpQOC 4.6FINSAngel Oak Financial Strategies Income Term TrustQOC 4.6JTAIJet.AI Inc.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DXR · EURK · FINS · JTAI · NVDA

Where Does AXIM Sit in CirclFi's Biotechnology Rankings?

AXIM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About AXIM Biotechnologies, Inc.’s Valuation?

What is AXIM Biotechnologies, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for AXIM Biotechnologies, Inc. (AXIM). The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AXIM overvalued or undervalued right now?

At $0.00, 1 of 1 active models suggest AXIM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits AXIM Biotechnologies, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.6 mean for AXIM?

AXIM Biotechnologies, Inc.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on AXIM?

CirclFi analyzes AXIM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is AXIM a value trap in 2026?

AXIM Biotechnologies, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns AXIM Biotechnologies, Inc. (AXIM) a Quality of Company score of 4.6/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/AXIM/ · Methodology
Primary sources for this AXIM valuation
  • Financial statements: AXIM Biotechnologies, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001514946) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AXIM as of ; valuations recomputed .